Clinical Trial Update: MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) [Phase 2]

View source ↗

Summary

Phase 2 trial MEND-CABG MC-1, designed to reduce necrosis and damage during coronary artery bypass graft surgery, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Ischemia
• Reperfusion Injury

Drugs mentioned

• MEND-CABG MC-1

Snippet

Sponsor: Medicure | Conditions: Coronary Artery Bypass Graft Surgery, Myocardial Ischemia | Phase 2 | Status: COMPLETED